Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Initiates Coverage On Day One Biopharmaceutical with Perform Rating

Oppenheimer analyst Matthew Biegler initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Perform rating.

byBenzinga Newsdesk

February 3, 2023

1 minute read

Oppenheimer analyst Matthew Biegler initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Perform rating.

Morgan Stanley Maintains Overweight on Capri Holdings, Raises Price Target to $70

By Benzinga Newsdesk

Today, 11:16 PM

Morgan Stanley analyst Kimberly Greenberger maintains Capri Holdings (NYSE:CPRI) with a Overweight and raises the price target from $68 to $70.

CPRI

News
Tech

UiPath Plans Job Cuts: All You Need To Know

By Anusuya Lahiri

Today, 11:16 PM

UiPath, Inc (NYSE:PATH) approved restructuring actions to manage its operating expenses. The measures will likely include an overall reduction of 5%…

PATH

News

‘Facebook launches program to help small Indian businesses secure loans’ -TechCrunch Report

By Benzinga Newsdesk

Today, 11:16 PM

https://techcrunch.com/2021/08/20/facebook-launches-program-to-help-small-and-medium-sized-indian-businesses-secure-loans/

News
Tech

Snapchat’s Bug Affected Some Users App Login

By Anusuya Lahiri

Today, 11:16 PM

Snap Inc (NYSE:SNAP) acknowledged that some Snapchat users faced logging difficulties while using the app. Four hundred and forty-seven users reported…

SNAP

Oppenheimer Initiates Coverage On Day One Biopharmaceutical with Perform Rating

Related Posts

Morgan Stanley Maintains Overweight on Capri Holdings, Raises Price Target to $70

UiPath Plans Job Cuts: All You Need To Know

‘Facebook launches program to help small Indian businesses secure loans’ -TechCrunch Report

Snapchat’s Bug Affected Some Users App Login